Omalizumab in patients with severe asthma: the XCLUSIVE study
- 9 August 2011
- journal article
- research article
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 6 (4), 215-227
- https://doi.org/10.1111/j.1752-699x.2011.00263.x
Abstract
Although the efficacy and safety of omalizumab (OMA) in uncontrolled severe allergic asthma has been demonstrated in several randomised controlled trials (RCTs), information on the treatment in a practice-related setting is limited. Thus, the purpose of this prospective multi-centre study (XCLUSIVE) was to investigate the efficacy, compliance and utilisation of OMA therapy in real-life clinical practice in Germany. One hundred ninety-five asthmatic patients initiated on anti-Immunoglobulin E (IgE) IgE treatment were followed-up for 6 months. Forced expiratory volume in 1 s (FEV(1) ), exacerbation rate, days of absence, asthma symptoms [Asthma Control Questionnaire (ACQ)], a Global Evaluation of Treatment Effectiveness (GETE) and medication use were assessed. Measured outcome variables improved after a 16-week treatment period with OMA (FEV(1) +13.7% predicted P < 0.05, exacerbation rate -74.9% P < 0.0001, days of absence -92.1% P < 0.001, ACQ -43.7% P < 0.0001). Investigators evaluated the effectiveness of OMA by GETE in 78.8% as excellent or good (responder), and in 12.6%/8.6% as moderate/poor or worse (non-responder). Responders demonstrated better improvement of FEV(1), exacerbation rate, days of absence, ACQ and reduction of oral corticosteroids compared with non-responders. Results of effectiveness strongly suggest that the efficacy demonstrated in RCTs can be transposed to a clinical practice-related setting.This publication has 31 references indexed in Scilit:
- Effects of climate change on environmental factors in respiratory allergic diseasesClinical & Experimental Allergy, 2008
- Global strategy for asthma management and prevention: GINA executive summaryEuropean Respiratory Journal, 2008
- Omalizumab (Xolair): Anti‐Immunoglobulin E Treatment in Allergic DiseasesPublished by Wiley ,2007
- Environmental risk factors and allergic bronchial asthmaClinical & Experimental Allergy, 2005
- The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammationJournal of Allergy and Clinical Immunology, 2005
- The global burden of asthma: executive summary of the GINA Dissemination Committee ReportAllergy, 2004
- The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthmaEuropean Respiratory Journal, 2003
- Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody.The Journal of Experimental Medicine, 1996
- Relation between Airway Responsiveness and Serum IgE in Children with Asthma and in Apparently Normal ChildrenThe New England Journal of Medicine, 1991
- Association of Asthma with Serum IgE Levels and Skin-Test Reactivity to AllergensThe New England Journal of Medicine, 1989